In clinical trials, for-profit review boards are taking over for hospitals. Should they?
By Sheila Kaplan,
STAT
| 07. 06. 2016
For years, ethicist Arthur Caplan warned medical researchers that paying businesses to evaluate their clinical trials was a bad idea.
He condemned trials that didn’t rely on hospital or academic review boards — long the gold standard in science — and argued that for-profit review boards were out to make a buck, not protect patients.
Today, Caplan sits on the advisory board of WIRB-Copernicus Group, the largest commercial institutional review board, or IRB, in the country.
He says he had no choice.
Continue reading on STAT
Image via Flickr/AJC
Related Articles
By Risa Cromer, The Conversation | 07.17.2026
By Emily Packard Dawson and Lainie Friedman Ross , The Hastings Center for Bioethics | 07.16.2026
Major news outlets recently reported – based on a bioRxiv preprint – that scientists had edited genes in human embryos with “startling precision.” The scientists’ decision to release this work ahead of peer review, coupled with the extensive media coverage...
By Julia Métraux, Mother Jones [cites CGS' Katie Hasson] | 07.07.2026
During his 2015 State of the Union address, then-President Barack Obama announced what he promised would be an ambitious public health project. “Tonight, I’m launching a new Precision Medicine Initiative to bring us closer to curing diseases like cancer and diabetes...
By Emily Baumgaertner Nunn, The New York Times | 06.30.2026
A research program at the National Institutes of Health released the world’s largest database of human genomes and paired them with clinical data, officials announced Tuesday, paving the way for a new era of study in personalized medicine.
The All...
